JAJames Jay Augsburger

James Jay Augsburger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


James Jay Augsburger has a total of 397 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Varicosity of Vortex Vein Ampulla in Ocular Fundus: Descriptive Series of 53 Patients and Literature Review

    by Jonathan T. Regenold, Zélia M. Corrêa, Robert H. Osher, James J. Augsburger

    Background/Objectives: Varicosities of the vortex vein ampulla are transient dilations of vortex vein ampullae that appear as red-brown choroidal masses. The purpose of this manuscript is to describe a retrospective case series of 53 patients with varicosities of the vortex vein ampulla and perform a literature review on this topic. Methods: Our case series demonstrates the clinical features of a large cohort of varicosities of the vortex vein ampulla, including their locations in the ocular fundus, sizes when congested, direction of gaze that resulted in detection, frequency of multiple lesions in a single eye, and frequency of bilateral cases. The literature review utilized PubMed and Embase libraries and included all studies published through December 2025. Results: The literature review yielded 44 articles, of which 36 were deemed relevant. Several studies described the appearance of these lesions using imaging modalities, including B-scan ultrasonography, optical coherence tomography, and indocyanine green angiography. Others underscored the potential for these lesions to be mistaken for other types of choroidal masses, such as choroidal melanomas. Conclusions: This extensive series demonstrates that these lesions are most often located nasally, sometimes multiple or bilateral, and often mistaken for choroidal nevi or melanomas, highlighting the importance of understanding clinical characteristics for appropriate diagnosis. In addition, some studies described possible associations with conditions such as nodular scleritis and Donnai–Barrow syndrome.

  • Open Access

    Varicosity of Vortex Vein Ampulla in Ocular Fundus: Descriptive Series of 53 Patients and Literature Review

    by Jonathan T. Regenold, Zélia M. Corrêa, Robert H. Osher, James J. Augsburger

    Background/Objectives: Varicosities of the vortex vein ampulla are transient dilations of vortex vein ampullae that appear as red-brown choroidal masses. The purpose of this manuscript is to describe a retrospective case series of 53 patients with varicosities of the vortex vein ampulla and perform a literature review on this topic. Methods: Our case series demonstrates the clinical features of a large cohort of varicosities of the vortex vein ampulla, including their locations in the ocular fundus, sizes when congested, direction of gaze that resulted in detection, frequency of multiple lesions in a single eye, and frequency of bilateral cases. The literature review utilized PubMed and Embase libraries and included all studies published through December 2025. Results: The literature review yielded 44 articles, of which 37 were deemed relevant. Several studies described the appearance of these lesions using imaging modalities, including B-scan ultrasonography, optical coherence tomography, and indocyanine green angiography. Others underscored the potential for these lesions to be mistaken for other types of choroidal masses, such as choroidal melanomas. Conclusions: This extensive series demonstrates that these lesions are most often located nasally, sometimes multiple or bilateral, and often mistaken for choroidal nevi or melanomas, highlighting the importance of understanding clinical characteristics for appropriate diagnosis. In addition, some studies described possible associations with conditions such as nodular scleritis and Donnai-Barrow syndrome.

  • Open Access

    Astrocytomas of Retina: Why Do Many Authors Still Refer to These Lesions as Astrocytic Hamartomas?

    by James J Augsburger

    Objective: To determine the prevalence of retinal astrocytic tumors in newborns. Methods: Analysis of published articles describing large-scale screening studies of newborns (pre-term and term) performed using wide-field digital fundus imaging in which authors reported fundus lesions and abnormalities other than retinopathy of prematurity and retinal hemorrhages; counting of the cases in which an ocular fundus lesion diagnosed as retinal astrocytoma or retinal astrocytic hamartoma was reported. Results: Fourteen published articles on ocular fundus screening examinations of > 1,000 newborns using digital wide-field fundus imaging (13 articles) or smart phone fundus imaging (1 article) reported fundus lesions and abnormalities other than retinopathy of prematurity in an aggregate total of over 300,000 cases. Only 1 newborn was reported to have a discrete retinal tumor diagnosed as a retinal astrocytic tumor by the authors. Conclusion: Although a few congenital lesions diagnosed as retinal astrocytic tumors have been documented, most lesions of this type do not appear to be congenital. In view of this, the term “retinal astrocytic hamartoma” (implying a congenital malformation) for all lesions of this type appears to be inappropriate.

  • Open Access

    Comparison of Cytopathology Yield of Fine-Needle Aspiration Biopsy Using 25G Versus 27G Needles for Melanocytic Uveal Tumors

    by Gustavo Rosa Gameiro, Carolina C. Valente, James J. Augsburger, Zelia M. Correa

    Background/Objectives: This study aims to evaluate whether fine-needle aspiration biopsy (FNAB) of melanocytic uveal tumors (MUTs) using 27-gauge (27G) needles yields aspirates like those obtained using 25-gauge (25G) needles for cytology. Methods: A retrospective review was conducted on 32 primary uveal melanomas (PUMs). Tumors were sampled at three adjacent sites, first using a 27G needle for gene expression profile (GEP) testing, second and third with 27G and 25G needles for cytology. The endpoints evaluated were the sufficiency of aspirates for cytopathology and GEP. Results: Among the 32 patients, 17 tumors were choroidal, 6 ciliochoroidal, 7 iridociliochoroidal, and 2 exclusively iridic. Tumor diameter ranged from 3.3 mm to 23 mm (mean 13.2 mm), and thickness ranged from 0.5 mm to 12 mm (mean 6.4 mm). Aspirates from both needle sizes were sufficient for cytopathological diagnosis and GEP in 31 of 32 cases (96.9%). The single insufficient aspirate was insufficient with both the 27G and 25G needles. The cytopathology was identical in all other cases. The tumors were Class 1 in 22 cases (71.0%) and Class 2 in 9 cases (29.0%). Conclusions: FNAB aspirates of MUTs using 27G needles appear sufficient for cytology and GEP in most cases, showing a similar diagnostic yield compared to 25G needles.

  • Open Access

    Comparison of Cytopathology Yield of Fine Needle Aspiration Biopsy Using 25G versus 27G Needles for Melanocytic Uveal Tumors

    by Gustavo Rosa Gameiro, Carolina Correa Valente, James Jay Augsburger, Zelia Maria Correa

    Background/Objectives: To evaluate whether fine needle aspiration biopsy (FNAB) of melanocytic uveal tumors (MUT) using 27-gauge (27G) needles yields aspirates like those obtained using 25-gauge (25G) needles for cytology. Methods: A retrospective review conducted on 32 primary uveal melanomas. Tumors were sampled at three adjacent sites first using a 27G needle for gene expression profile (GEP) testing, the second and third with a 27G and 25G needles for cytology. The endpoints evaluated were the sufficiency of aspirates for cytopathology and GEP. Results: Among the 32 patients, 17 tumors were choroidal, 6 ciliochoroidal, 7 iridociliochoroidal, and 2 exclusively iridic. Tumor diameter ranged from 3.3 mm to 23 mm (mean 13.2 mm) and thickness from 0.5 mm to 12 mm (mean 6.4 mm). Aspirates from both needle sizes were sufficient for cytopathological diagnosis and GEP in 31 of 32 cases (96.9%). The single insufficient aspirate was insufficient with both the 27G and 25G needles. Cytopathology was identical in all other cases. Tumors were Class 1 in 22 cases (71.0%) and Class 2 in 9 cases (29.0%). Conclusions: FNAB aspirates of MUTs using 27G needles appear sufficient for cytology and GEP in most cases showing similar diagnostic yield compared to 25G needles.


  • MALIGNANT TRANSFORMATION OF A CHOROIDAL NEVUS AFTER 19 YEARS OF OBSERVATION FOLLOWED BY RAPID PROGRESSION OF THE CHOROIDAL MELANOMA

    by Hannah M. Bs Istre-Wilz, Maura Di Nicola, James J. Augsburger, Basil K. Jr Williams

    Purpose: To describe the case of a woman who developed rapid progression of a choroidal melanoma after 19 years of observation of a previously treated choroidal nevus. Methods: A 71-year-old woman with a 22-year history of a choroidal nevus was observed for 19 years after undergoing transpupillary thermotherapy for a localized, macula-involving, exudative, retinal detachment. Five months after her most recent stable examination, she presented for routine follow-up. Results: The lesion was noted to have increased thickness with the development of lipofuscin and subretinal fluid, suggestive of malignant transformation. In the 1 month between diagnosis and treatment with iodine-125 plaque brachytherapy, the lesion continued to expand, requiring a radiation dose adjustment. Conclusion: Choroidal nevus transformation into melanoma has been well-documented, highlighting the need for routine follow-up. Treatment within 1 month is typically sufficient for appropriate management. Occasionally, melanomas may grow substantially between diagnosis and treatment, suggesting that repeat measurement may be necessary in rare instances to ensure appropriate radiation treatment.

  • Open Access

    Second Primary Malignant Neoplasms in Survivors of Retinoblastoma in a Single Ocular Oncology Practice

    by Malcolm T. Wiseman, Jared J. Ebert, James J. Augsburger, Maura Nicola, Zelia M. Correa, James Geller, Basil K. Williams

    Background: To describe the clinical features and course of a series of survivors of retinoblastoma who developed a non-pineoblastoma second primary malignant neoplasm (SPMN). Methods: A retrospective review of patients treated for retinoblastoma who developed a SPMN was performed. The demographics, clinical features and treatments for retinoblastoma, pathologic types of SPMN, the intervals between the retinoblastoma diagnosis and treatment and diagnosis of non-pineoblastoma SPMN, treatment provided for the SPMN, and the survival outcomes of the patients were evaluated. Results: Of 550 patients treated initially for retinoblastoma, this series used the 15 (2.7%) that developed a non-pineoblastoma SPMN, 14 of which (93.3%) had been treated for bilateral retinoblastoma. All patients in this series had germline retinoblastoma. The median time from retinoblastoma diagnosis to SPMN diagnosis was 19.0 years (extremes 3.4 and 39.4 years). Six of the fifteen patients died during the follow-up of their SPMN. Nine patients were still alive without active residual SPMN at the last follow-up. The median interval between initial retinoblastoma diagnosis and death in the 6 patients who died of their SPMN was 18.8 years (extremes 6.2 and 34.6 years) and between diagnosis of the SPMN and death was 1.2 years (extremes 0.25 and 4 years). Conclusion: A SPMN occurred in this series in 2.7% of retinoblastoma survivors, and all occurred in patients with germline retinoblastoma. All patients with SPMN who had been treated by EBRT developed the SPMN in the field of prior radiation.

  • Open Access

    Response to Cook and Alsina’s Letter to Editor (Reply to Augsburger et al.)

    by James J. Augsburger, Cassandra C. Skinner, Zelia M. Correa

    Dear Editor,We appreciate Cook and Alsina’s interest in our recently published article [1] and are pleased to respond to their comments about our work.

  • Comparative Metastatic Rates in GEP Class 1A versus 1B Posterior Uveal Melanoma: Results Contrary to Expectations

    by James J. Augsburger, Cassandra C. Skinner, Zelia M. Correa

    Purpose: The purpose of this study was to determine whether the metastatic rates in patients with gene expression profile (GEP) class 1A versus 1B posterior uveal malignant melanoma supported or contradicted predictions of very low metastatic rate in GEP 1A cases and moderate rate in GEP 1B cases. Patients/Methods: 164 patients with a cytopathologically confirmed primary posterior uveal malignant melanoma classified by GEP testing as class 1 (100 GEP 1A, 64 GEP 1B) were evaluated. Kaplan-Meier rates of metastasis were computed and plotted for the GEP class 1 subgroups. Median follow-up of patients who were still alive without metastasis on the date of data analysis was 100.5 months for the GEP 1A patients and 97.2 months for the GEP 1B patients. Results: The actuarial 5-year rate of uveal melanoma metastasis was 10.8% (std. error = 3.2%) in the GEP 1A patients versus 0% in the GEP 1B patients, and the actuarial 10-year rate of metastasis was 12.2% (std. error = 3.5%) in the GEP 1A patients versus 2.1% (std. error 2.1%) in the GEP 1B patients. Conclusion: The results of this retrospective single-center study cast doubt on the validity of the prognostic stratification of GEP class 1 posterior uveal malignant melanomas into very low risk (GEP 1A) versus intermediate risk (GEP 1B) of metastasis subgroups provided by the commercially available GEP test.